Passage Bio (PASG) Stock Forecast & Price Target

$0.70

0.00 (-0.14%)

(As of 02:53 PM ET)

Passage Bio - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 3 Analyst Ratings

Based on 3 Wall Street analysts who have issued ratings for Passage Bio in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 3 have given a buy rating for PASG.

Consensus Price Target

$8.33
1,090.48% Upside

High Forecast	$13.00
Average Forecast	$8.33
Low Forecast	$5.00

According to the 3 analysts' twelve-month price targets for Passage Bio, the average price target is $8.33. The highest price target for PASG is $13.00, while the lowest price target for PASG is $5.00. The average price target represents a forecasted upside of 1,090.48% from the current price of $0.70.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$8.33	$9.00	$9.00	$8.40
Forecasted Upside	1,090.48% Upside	847.37% Upside	887.20% Upside	600.65% Upside

“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!” (Ad)

Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.

Go here for the full details now.

PASG Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PASG Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Passage Bio Stock vs. The Competition

Type	Passage Bio	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	1,088.78% Upside	1,006.91% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/3/2024	Rodman & Renshaw 1 of 5 stars		Initiated Coverage	Buy	$7.00	+899.13%
5/15/2024	Canaccord Genuity Group 1 of 5 stars		Lower Target	Buy ➝ Buy	$14.00 ➝ $13.00	+899.99%
11/14/2023	Raymond James 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$9.00 ➝ $5.00	+733.32%
8/7/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$11.00 ➝ $9.00	+977.83%
3/6/2023	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Chico Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
11/16/2022	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$9.00	+542.85%
11/11/2022	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$13.00 ➝ $11.00	+727.06%
11/11/2022	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$7.00 ➝ $5.00	+275.94%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:17 PM ET.

PASG Forecast - Frequently Asked Questions

What is Passage Bio's forecast for 2024?: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Passage Bio is $8.33, with a high forecast of $13.00 and a low forecast of $5.00.
Should I buy or sell Passage Bio stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PASG shares.
Does Passage Bio's stock price have much upside?: According to analysts, Passage Bio's stock has a predicted upside of 861.32% based on their 12-month stock forecasts.
What analysts cover Passage Bio?: Passage Bio has been rated by research analysts at Rodman & Renshaw in the past 90 days.
Do Wall Street analysts like Passage Bio more than its competitors?: Analysts like Passage Bio more than other "medical" companies. The consensus rating for Passage Bio is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PASG compares to other companies.